Pseudoprogression of triple-hit diffuse large B-cell lymphoma following polatuzumab vedotin-based salvage therapy

Leuk Lymphoma. 2021 Aug;62(8):2022-2025. doi: 10.1080/10428194.2021.1894646. Epub 2021 Mar 15.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Humans
  • Immunoconjugates* / therapeutic use
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Lymphoma, Large B-Cell, Diffuse* / genetics
  • Salvage Therapy

Substances

  • Antibodies, Monoclonal
  • Immunoconjugates
  • polatuzumab vedotin